Research programme: musculoskeletal therapeutics - Arcarios

Drug Profile

Research programme: musculoskeletal therapeutics - Arcarios

Alternative Names: ARC-118; ARC-205; BMP modulators - Arcarios

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator TiGenix
  • Developer Arcarios
  • Class Recombinant fusion proteins; Small molecules
  • Mechanism of Action Activin receptor antagonists; Bone morphogenetic protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fracture; Multiple myeloma; Osteoporosis
  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Belgium (Intra-articular, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Belgium (SC, Injection)
  • 01 Jan 2014 Preclinical trials in Fracture treatment in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top